- Sodium
- Sodium (+)-10-camphorsulfonate
- Sodium 2-(4-methoxyphenoxy)propionate
- Sodium 2,4-dinitrophenate
- Sodium 2,5-difluorobenzoate
- Sodium 2-bromoethanesulphonate
- Sodium 2-carboxy-4-sulfobenzoate
- Sodium 2-chloro-5-nitrobenzenesulfonate
- Sodium 2-ethylhexanoate
- Sodium 2-ethylhexyl sulfate
- 21267-14-11,4-bis(diethoxyphosphoryl)benzene
- 2126-78-5Ergoline-8-carboxamide,9,10-didehydro-N,N-diethyl-6-methyl-, (8a)-
- 21267-92-54-[[[9-(5-diethylaminopentan-2-yl)purin-6-yl]amino]methyl]benzenesulfonamide
- 21267-93-64-[2-[[9-(5-diethylaminopentan-2-yl)purin-6-yl]amino]ethyl]benzenesulfonamide
- 2126-91-2(1)-alpha,2-Diamino-gamma-oxobenzenebutyric acid, sulphate (1:1)
- 21269-34-14-Quinolinol,8-methoxy-
- 21269-61-43,6,6-trimethyl-1-phenyl-6,7-dihydro-1H-indazol-4(5H)-one
- 21270-07-5Benzene,1-[2-bromo-1-[(2-ethylhexyl)oxy]ethyl]-4-hexyl-
- 2127-01-71H-Isoindole-5-sulfonamide,6-chloro-2-cyclohexyl-2,3-dihydro-3-oxo-
- 2127-03-9Pyridine,2,2'-dithiobis-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Sodium β-4-methoxybenzoyl-β-bromoacrylate |
EINECS | N/A |
| CAS No. | 2126-70-7 | Density | N/A |
| PSA | 63.60000 | LogP | 2.24130 |
| Solubility | N/A | Melting Point |
N/A |
| Formula | C11H8BrO4•Na | Boiling Point | N/A |
| Molecular Weight | 307.09 | Flash Point | N/A |
| Transport Information | N/A | Appearance | N/A |
| Safety | Poison by intraperitoneal route. Moderately toxic by intravenous route. Human systemic effects by intravenous route: hallucinations, distorted perceptions, motor activity changes and nausea or vomiting. Mutation data reported. When heated to decomposition it emits toxic fumes of Br− and Na2O. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
(Z)-3-(p-Anisoyl)-3-bromoacrylic acid sodium salt;2-Butenoic acid,3-bromo-4-(4-methoxyphenyl)-4-oxo-,sodium salt,(Z); |
Sodium β-4-methoxybenzoyl-β-bromoacrylate Chemical Properties
IUPAC Name: Sodium (Z)-3-bromo-4-(4-methoxyphenyl)-4-oxo-but-2-enoate
Synonyms of Sodium β-4-methoxybenzoyl-β-bromoacrylate (CAS NO.2126-70-7) : 2-Butenoic acid, 3-bromo-4-(4-methoxyphenyl)-4-oxo-, sodium salt ; 2-Butenoic acid, 3-bromo-4- (4-methoxyphenyl)-4-oxo-, sodium salt, (Z)- ; 2-Butenoic acid, 3-bromo-4-(4-methoxyphenyl)-4-oxo-, sodium salt, (2Z)- (1:1) ; Sodium (2Z)-3-bromo-4-(4-methoxyphenyl)-4-oxo-2-butenoate
CAS NO: 2126-70-7
Molecular Formula:C11H8BrNaO4
Molecular Weight :307.0726
Molecular Structure :.png)
Flash Point: 206.5 °C
Enthalpy of Vaporization: 70.78 kJ/mol
Boiling Point: 417.9 °C at 760 mmHg
Vapour Pressure: 9.92E-08 mmHg at 25°C
Sodium β-4-methoxybenzoyl-β-bromoacrylate Uses
Sodium β-4-methoxybenzoyl-β-bromoacrylate (CAS NO.2126-70-7) is used as intermediate in organic synthesis.
Sodium β-4-methoxybenzoyl-β-bromoacrylate Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LDLo | intravenous | 200mg/kg (200mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: PROTEINURIS BLOOD: OTHER CHANGES | Cancer Chemotherapy Reports, Part 1. Vol. 59, Pg. 1071, 1975. |
| human | TDLo | intravenous | 60mg/kg/5D (60mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: NAUSEA OR VOMITING | Journal of the National Cancer Institute. Vol. 59, Pg. 1619, 1977. |
| mouse | LD50 | intraperitoneal | 49720ug/kg (49.72mg/kg) | National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986, | |
| mouse | LD50 | intravenous | 98mg/kg (98mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Neoplasma. Vol. 16, Pg. 121, 1969. |
| mouse | LD50 | subcutaneous | 52mg/kg (52mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: FOOD INTAKE (ANIMAL) | Neoplasma. Vol. 16, Pg. 121, 1969. |
| rat | LD50 | intraperitoneal | 155mg/kg (155mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: FOOD INTAKE (ANIMAL) | Neoplasma. Vol. 16, Pg. 121, 1969. |
| rat | LD50 | intravenous | 245mg/kg (245mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Neoplasma. Vol. 16, Pg. 121, 1969. |
| rat | LD50 | subcutaneous | 155mg/kg (155mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: FOOD INTAKE (ANIMAL) | Neoplasma. Vol. 16, Pg. 121, 1969. |
Sodium β-4-methoxybenzoyl-β-bromoacrylate Consensus Reports
EPA Genetic Toxicology Program.
Sodium β-4-methoxybenzoyl-β-bromoacrylate Safety Profile
Poison by intraperitoneal route. Moderately toxic by intravenous route. Human systemic effects by intravenous route: hallucinations, distorted perceptions, motor activity changes and nausea or vomiting. Mutation data reported. When Sodium β-4-methoxybenzoyl-β-bromoacrylate (CAS NO.2126-70-7) is heated to decomposition it emits toxic fumes of Br− and Na2O.
What can I do for you?
Get Best Price
